A small number of HIV-1 infected individuals develop broadly neutralizing-antibodies to 25 the virus (bNAbs). These antibodies are protective against infection in animal models. 26
antibody repertoires [13] [14] [15] [16] [17] [18] . However, even in transgenic mice that carry super-physiologic 48 frequencies of bNAb precursors, antibody maturation required multiple immunizations 49 with a number of different sequential immunogens. Moreover, bNAbs only developed for 50 one of the epitopes targeted 15, 17, 18 . Consequently, elicitation of bNAbs in primates or 51 humans remains a significant challenge. 
Antibody gene editing in human B cells 135
To determine whether this method could be adapted to edit human B cells we isolated 136 them from peripheral blood of healthy volunteers and activated them using an anti-137 human RP105 antibody 32 . Analogous crRNAs were selected for targeting the human 138 IGKC and the first intron 3' of IGHJ6 ( Fig.3a-d, Supplementary Fig.5a-b) . The best 139 IGKC-targeting crRNA caused 85 % of k-bearing B cells to lose BCR expression, 140 whereas l-bearing cells increased proportionally indicating that they were unaffected. 141 TIDE analysis of the JH6 intron sequences showed that the most efficient crRNA 142 induced 64% indels. In conclusion, activation of human, primary B cells with anti-RP105 143 allows efficient generation of indels using Cas9 RNPs. 144
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To target bNAbs into the human JH6 intron we adapted the ssDNA HDRT and replaced 146 mouse with human homology arms, the human Cµ splice acceptor, the human IGHV1-147 69 promoter, a codon-modified human IGKC constant region to avoid targeting by 148 crRNAs and the human JH4 splice donor (Fig 3a) . In contrast to mouse cells, 2.9 -4 % 149 of l -B cells expressed 3BNC60 SI or 10-1074 antibodies respectively as determined by 150 flow cytometry using the cognate antigen (Fig 3e,f) . Thus, the efficiency of transgene 151 integration is at least 10-times higher in human B cells. Furthermore, viability was also 152 higher in human B cells, ranging from 60 to 85 % of live cells after transfection 153
( Supplementary Fig.5c ). 154
155
We conclude that primary human B cells can be edited by CRISPR/Cas9 to express 156 anti-HIV bNAbs, and that this is significantly more efficient than in mouse B cells. 157
158

Adoptive transfer of antibody-edited B cells 159
To determine whether edited B cells can participate in immune responses, we 160 adoptively transferred mouse 3BNC60 SI -edited Igh b B cells, into congenically-marked 161
Igh a wild type mice and immunized with the high-affinity, cognate antigen TM4 core in 162
Ribi adjuvant (Fig.4a) . Transgene-specific responses were detected using anti-idiotypic 163 antibodies as an initial capture reagent in ELISA. Similar to endogenous humoral 164 immune responses, transgenic antibodies were detected on day 7 after immunization, 165 they peaked at day 14 and started to decrease by day 21 (Fig.4b, c) . Importantly, the 166 transgenic immune response included secondary isotypes indicating that the re-167 9 engineered locus supports class switch recombination (Fig.4c) . Finally, the magnitude 168 of the response was directly correlated to the number of transferred cells. However, 169 prolonged in vitro culture under the conditions tested decreased the efficiency of 170 antibody production in vivo (Fig.4d) . 171
172
To determine whether the transferred cells retained the ability to produce neutralizing 173 antibodies we used B cells that were edited to produce 10-1074, a potent bNAb, or 174 3BNC60 SI a chimeric antibody with limited neutralizing activity 31, 33 . 4 × 10 7 transfected 175 B cells were transferred into wild type Igh a mice that were subsequently immunized with 176 the appropriate cognate antigen 10mut 29 or TM4 core 16, 27, 28, 31 . Serum IgG was purified 177 from 3 mice each that received an estimated ~10 3 edited B cells expressing 10-1074 or 178 3BNC60 SI . The serum antibodies were tested for neutralizing activity in the TZM-bl 179 assay 34 . Two of the 3 mice that received 10-1074 edited cells showed IC50s of 21.59 180 µg/mL and a third reached 49 % neutralization at 118 µg/mL (corresponding to 181 approximately 1:500 and 1:100 dilution of serum, Fig.4e, Supplementary Fig.6a, b) . As 182 expected, neutralizing activity was not detected in mice receiving 3BNC60 SI because 183 this antibody is 2 -3 orders of magnitude less potent against the tested viral strains than 184 10-1074 ( Supplementary Fig.6e) . 185
186
We conclude that edited B cells can be recruited into immune responses and produce 187 sufficient antibody to confer potentially protective levels of humoral immunity 35 . antibody at 2 µg/mL and incubated at 37°C 5 % CO2 for 24 h before further processing. 337
338
TIDE assay 339
Genomic DNA was extracted from 0.5 -5 × 10 5 cells by standard phenol/chloroform 340 extraction 24 -42 h after transfection. PCRs to amplify human or mouse Ig loci targeted 341 by CRISPR-Cas9 were performed using Phusion Green Hot Start II High-Fidelity 342 polymerase (Thermo Fisher Cat.# F-537L) and primers listed in Supplementary Table 3 . 343
Thermocycler was set to 40 cycles, annealing at 65°C for 30 s and extending at 72°C 344 for 30s. PCR product size was verified by gel electrophoresis, bands gel-extracted and 345 sent for Sanger sequencing (Genewiz) using the relevant PCR primers. ab1 files were 346 analyzed using the TIDE web tool (tide.nki.nl) using samples receiving scamble or 347 irrelevant HPRT-targeting crRNA as reference 23 . 348
Flow cytometry 349
Mouse spleens were forced through a 70 µm mesh into FACS buffer (PBS containing 2 350 % heat-inactivated FBS and 2 mM EDTA) and red blood cells were lysed in ACK lysing 351 buffer (Gibco) for 3 min. 
Anti-idiotypic antibody 383
IgG producing hybridomas were isolated from mice immunized with iGL-VRC01 at the 384
Frederick Hutchinson Cancer Research Center Antibody Technology Resource. 385
Hybridoma supernatants were screened against a matrix of inferred germline (iGL) 386 VRC01 class antibodies as well as irrelevant iGL-antibodies using a high throughput 387 bead-based assay. One anti-idiotypic antibody, clone iv8, bound to additional VRC01 388 class antibodies, but it also bound to a chimeric antibody with an iGL-VRC01 class light 389 chain paired with the 8ANC131 heavy chain (which is derived from VH1-46), and to 390 3BNC60 SI . 391 392 20
ELISAs 393
For determination of 3BNC60 SI levels, Corning 3690 half-well 96-well plates were 394 coated overnight at 4°C with 25 µL/well of 2 µg/mL human anti-3BNC60 SI (clone iv8) 395
IgG in PBS, then blocked with 150 µL/well PBS 5% skimmed milk for 2 h at room 396 temperature (RT). Sera were diluted to 1:50 with PBS and 7 subsequent 3-fold dilutions. 397
Recombinant 3BNC60 SI (produced in house as mouse IgG1,k) was diluted to 10 µg/mL 398 in PBS followed by six 5-fold dilutions. Blocked plates were washed 4-times with PBS 399 0.05 % Tween 20 and incubated with 25 µL diluted sera or antibody for 2 h at RT. 
